What is Jazz Pharmaceuticals plc's Shariah compliance score?

Jazz Pharmaceuticals plc's (JAZZ) compliance score is being calculated. Check HalalScreener.app for the latest AAOIFI screening results.

Does Jazz Pharmaceuticals plc pass AAOIFI screening?

Jazz Pharmaceuticals plc (JAZZ) does not pass AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (JAZZ: 36.2%), (3) interest-bearing deposits below 30% (JAZZ: 9.4%), and (4) prohibited income below 5% (JAZZ: 3.1%). HalalScreener provides free AAOIFI screening for 10,000+ stocks at halalscreener.app.

How much purification is needed for Jazz Pharmaceuticals plc stock?

Jazz Pharmaceuticals plc (JAZZ) has a non-permissible income ratio of 3.07%. Muslim investors should purify this percentage of any dividends received and capital gains realized from JAZZ shares by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification automates this calculation using the latest financial data.

Where can I screen Jazz Pharmaceuticals plc for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Jazz Pharmaceuticals plc (JAZZ) and 10,000+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows all financial ratios transparently. No credit card or signup required for basic screening. HalalScreener also includes an AI Islamic Scholar for follow-up questions about JAZZ's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

Is Jazz Pharmaceuticals plc (JAZZ) halal? Not Halal. Based on AAOIFI screening, Jazz Pharmaceuticals plc passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

JAZZ: Is Jazz Pharmaceuticals plc Halal?

Not Halal

Jazz Pharmaceuticals plc

NASDAQHealthcareUS

$236.17

+2.85%

AvoidBorderlineClean

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is a global biopharmaceutical firm dedicated to discovering, advancing, and bringing to market innovative medicines for conditions where treatment options are lacking, serving patients across the United States, Europe, and other international regions. Its extensive portfolio of both commercialized therapies and development candidates primarily focuses on neuroscience, particularly sleep disorders and movement conditions, alongside oncology, addressing both hematologic (blood) cancers and solid tumors. Among its principal marketed products are Xyrem, an oral solution managing cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients aged seven and older; Sunosi, also for EDS but in individuals with narcolepsy and obstructive sleep apnea; Erwinaze, targeting acute lymphoblastic leukemia; Defitelio, which treats hepatic veno-occlusive disease in adults and children; Vyxeos liposome for injection, indicated for adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca, prescribed for adult patients with metastatic small cell lung cancer. The company's developmental pipeline features Xywav, an oxybate candidate intended for EDS and cataplexy linked to narcolepsy, as well as idiopathic hypersomnia; JZP-324, a low-sodium oxybate formulation aiming to offer a significant alternative for narcolepsy patients; JZP385, a T-type calcium channel modulator being explored for essential tremor; JZP458, a recombinant Erwinia asparaginase used in multi-agent chemotherapy for both pediatric and adult patients; and JZP150, a compound under investigation for post-traumatic stress disorder. Jazz Pharmaceuticals maintains strategic licensing and collaborative partnerships with entities such as ImmunoGen, Inc., Codiak BioSciences, Inc., Pfenex, Inc., XL-protein GmbH, and Redx Pharma plc. Established in 2003, Jazz Pharmaceuticals plc operates from its headquarters in Dublin, Ireland.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Jun 12, 2026

Non-Compliant

Fails Shariah screening

0Score

Business Activity Screen

Passed

Checks if the business is involved in prohibited activities (alcohol, gambling, pork, conventional banking, etc.)

Financial Ratio Screen

Failed

Financial ratios must be below AAOIFI thresholds

Debt / Market Cap36.2% / 30.0%

Compliance History

Not Halal, unchanged since May 2026.

No status changes recorded since we began tracking.

Tracked since May 2026. Updates automatically on each re-screen.

Screened: Jun 12, 2026Fiscal: Q1 2026Source: FMP

Financial Overview

Market Cap

14.8B

Price

$236.17

Sector

Healthcare

Industry

Biotechnology

Halal Alternatives in Healthcare

This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:

0001.KLA+

Supercomnet Technologies Bhd

$0.54

+0.00%

0002.KLA+

Kotra Industries Bhd

$3.75

+0.00%

0075.KLA+

LYC Healthcare Bhd

$0.02

+0.00%

0101.KLA+

TMC Life Sciences Bhd

$0.45

+0.00%

0155.KLA+

Malaysian Genomics Resource Centre Bhd

$0.27

+0.00%

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+

Free · No credit card required

Track JAZZ and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Jazz Pharmaceuticals plc (JAZZ) halal to invest in?

Jazz Pharmaceuticals plc (JAZZ) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.

Why did Jazz Pharmaceuticals plc get a F compliance rating?

Jazz Pharmaceuticals plc (JAZZ) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 36.2% (limit 30%); interest-bearing deposits of 9.4% (limit 30%); prohibited income of 3.07% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Jazz Pharmaceuticals plc's Shariah verdict?

Jazz Pharmaceuticals plc's verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Jazz Pharmaceuticals plc re-screened for Shariah compliance?

Jazz Pharmaceuticals plc (JAZZ) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jun 12, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.